Literature DB >> 30858545

Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma.

Aiping Luo1, Xuantong Zhou1, Xing Shi2, Yahui Zhao1, Yu Men3, Xiao Chang3, Hongyan Chen1, Fang Ding1, Yi Li1, Dan Su4, Zefen Xiao5, Zhouguang Hui6, Zhihua Liu7.   

Abstract

Cancer cells associated with radioresistance are likely to give rise to local recurrence and distant metastatic relapse. However, it remains unclear whether specific miRNAs have direct roles in radioresistance and/or prognosis. In this study, we find that miR-339-5p promotes radiosensitivity, and is downregulated in radioresistant subpopulations of esophageal cancer cells. Notably, miR-339-5p was selectively secreted into blood via exosomes, and that higher serum miR-339-5p levels were positively associated with radiotherapy sensitivity and good survival. Moreover, miR-339-5p expression was downregulated in the T3/T4 stage compared with T1/T2 stage in esophageal squamous cell carcinoma (ESCC) patients (P = 0.04), and low miR-339-5p expression in tissue was significantly associated with poor overall survival (P = 0.036) and disease-free survival (P = 0.037). Overexpression of miR-339-5p enhanced radiosensitivity in vitro and in vivo. Mechanistically, miR-339-5p enhances radiosensitivity by targeting Cdc25A, and is transcriptionally regulated by Runx3. Correlations were observed between miR-339-5p levels and Cdc25A/Runx3 levels in tissue samples. Intriguingly, combined analysis of miR-339-5p expression with Runx3 increased the separation of the survival curves obtained for either gene alone in the TCGA datasets (P = 0.009). Overall, exosome-derived miR-339-5p mediates radiosensitivity through downregulation of Cdc25A, and predicts pathological response to preoperative radiotherapy in locally advanced ESCC, suggesting it could be a promising non-invasive biomarker for facilitating personalized treatments.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30858545     DOI: 10.1038/s41388-019-0771-0

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.

Authors:  Takaharu Kawai; Mitsugu Kochi; Masashi Fujii; Keio Song; Ken Hagiwara; Megumu Watanabe; Yoritaka Matsuno; Hiroshi Suda; Renpei Yagi; Tadatoshi Takayama
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

2.  Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.

Authors:  Yoichi Hamai; Jun Hihara; Manabu Emi; Takaoki Furukawa; Yuta Ibuki; Ichiko Yamakita; Tomoaki Kurokawa; Morihito Okada
Journal:  Anticancer Res       Date:  2017-10       Impact factor: 2.480

  2 in total
  25 in total

1.  Circular RNAs With Efficacy in Preclinical In Vitro and In Vivo Models of Esophageal Squamous Cell Carcinoma.

Authors:  Ulrich H Weidle; Tatjana Sela; Ulrich Brinkmann; Jens Niewoehner
Journal:  Cancer Genomics Proteomics       Date:  2022 May-Jun       Impact factor: 4.069

Review 2.  Extracellular vesicles and particles impact the systemic landscape of cancer.

Authors:  Serena Lucotti; Candia M Kenific; Haiying Zhang; David Lyden
Journal:  EMBO J       Date:  2022-09-02       Impact factor: 14.012

3.  Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1α.

Authors:  Baoqing Tian; Jiandong Liu; Nasha Zhang; Yemei Song; Yeyang Xu; Mengyu Xie; Bowen Wang; Hui Hua; Yue Shen; Yankang Li; Ming Yang
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

Review 4.  Radiotherapy resistance: identifying universal biomarkers for various human cancers.

Authors:  Irina Larionova; Militsa Rakina; Elena Ivanyuk; Yulia Trushchuk; Alena Chernyshova; Evgeny Denisov
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-03       Impact factor: 4.322

5.  Exosomal microRNA-26b-5p down-regulates ATF2 to enhance radiosensitivity of lung adenocarcinoma cells.

Authors:  Fushi Han; Dongdong Huang; Xinghong Huang; Wei Wang; Shusong Yang; Shuzhen Chen
Journal:  J Cell Mol Med       Date:  2020-05-31       Impact factor: 5.310

Review 6.  Extracellular Vesicles in Modifying the Effects of Ionizing Radiation.

Authors:  Tünde Szatmári; Rita Hargitai; Géza Sáfrány; Katalin Lumniczky
Journal:  Int J Mol Sci       Date:  2019-11-06       Impact factor: 5.923

7.  Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL‑6 in vitro and in vivo.

Authors:  Si Chen; Yanping Tang; Chun Yang; Kezhi Li; Xiaoqing Huang; Ji Cao
Journal:  Int J Mol Med       Date:  2020-01-09       Impact factor: 4.101

8.  LINC00473 contributes to the radioresistance of esophageal squamous cell carcinoma by regulating microRNA‑497‑5p and cell division cycle 25A.

Authors:  Wei-Hua Liu; Han-Yong Qiao; Jian Xu; Wei-Qing Wang; Yi-Lei Wu; Xia Wu
Journal:  Int J Mol Med       Date:  2020-05-25       Impact factor: 4.101

Review 9.  The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer.

Authors:  Linda Hofmann; Sonja Ludwig; Julius M Vahl; Cornelia Brunner; Thomas K Hoffmann; Marie-Nicole Theodoraki
Journal:  Int J Mol Sci       Date:  2020-06-06       Impact factor: 5.923

10.  miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25A (CDC25A).

Authors:  Feng-Na Ding; Bao-Hong Gao; Xia Wu; Chun-Wu Gong; Wei-Qing Wang; Shu-Mao Zhang
Journal:  FEBS Open Bio       Date:  2019-09-29       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.